SCHEMBL6760090

SCHEMBL6760090

Cc1c(Cl)ccc(S(=O)(=O)N(CCc2ccccc2)CC(=O)NCC(=O)N(CCN2CCCC2)Cc2ccc(C(=N)N)cc2)c1Cl

nearest known ligand 0.91

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
BDKRB1 P46663 3/20 0.91
F10 P00742 1/20 0.37
F2 P00734 3/20 0.37
TP53 P04637 1/20 0.34
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
LMNA P02545 2/20 0.34
OPRM1 P35372 1/20 0.34
OPRD1 P41143 1/20 0.34
MAPT P10636 1/20 0.34
HTT P42858 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
PRSS1 P07477 1/20 0.34
POLB P06746 1/20 0.33
ALDH1A1 P00352 1/20 0.33
AHCY P23526 1/20 0.33
AVPR1A P37288 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6761694 0.96 BDKRB1 (0.96) BDKRB1F10F2AVPR1A
SCHEMBL6761801 0.95 BDKRB1 (1.00) BDKRB1F10F2MEN1KMT2A
SCHEMBL6762376 0.92 BDKRB1 (0.78) BDKRB1F10F2TP53OPRM1
SCHEMBL6762372 0.92 BDKRB1 (0.78) BDKRB1F10F2TP53OPRM1
SCHEMBL6759967 0.90 BDKRB1 (0.75) BDKRB1F10TP53MEN1KMT2A
SCHEMBL6759964 0.90 BDKRB1 (0.75) BDKRB1F10TP53MEN1KMT2A
SCHEMBL6760095 0.89 BDKRB1 (0.73) BDKRB1TP53MEN1KMT2ALMNA
SCHEMBL6761731 0.89 BDKRB1 (0.73) BDKRB1TP53OPRM1OPRD1
SCHEMBL6763203 0.88 BDKRB1 (0.83) BDKRB1F10F2MEN1KMT2A
SCHEMBL6763320 0.88 BDKRB1 (0.83) BDKRB1F10F2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040063725-A1 Novel n(phenylsulphonyl)glycine derivatives and their therapeutic use LABORATORIES FOURNIER S.A. (FR) 2004-04-01 US disclosed
EP-1351928-A2 NOVEL N(PHENYLSULPHONYL)GLYCINE DERIVATIVES AND THEIR THERAPEUTIC USE LABORATOIRES FOURNIER S.A. (FR) 2003-10-15 EP disclosed
EP-1268418-A1 PHARMACEUTICALLY ACTIVE PYRROLIDINE DERIVATIVES AS BAX INHIBITORS Applied Research Systems ARS Holding N.V. (AN) 2003-01-02 EP disclosed
WO-2002053516-A2 N(PHENYLSULPHONYL)GLYCINE DERIVATIVES AND THEIR THERAPEUTIC USE LABORATOIRES FOURNIER SA (FR) 2002-07-11 WO disclosed
WO-2001074769-A1 PHARMACEUTICALLY ACTIVE PYRROLIDINE DERIVATIVES AS BAX INHIBITORS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2001-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063725-A1 Novel n(phenylsulphonyl)glycine derivatives and their therapeutic use GLS, GLS2, GLRB BDKRB1 481/4885F10 4430/4885F2 3682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.